A prospective, randomized, controlled trial comparing three different gonadotropin regimens in oocyte donors: ovarian response, in vitro fertilization outcome, and analysis of cost minimization.
OBJECTIVE
To compare the efficacy of three different gonadotropin regimens in an oocyte donation program. The analysis of cost minimization also was evaluated.


METHODS
Prospective, randomized, controlled study.


METHODS
Instituto Universitario-IVI, Valencia, Spain.


METHODS
One thousand twenty-eight donors undergoing a GnRH agonist protocol were assigned randomly to one of three groups: group 1 (n=346), only recombinant FSH (rFSH); group 2 (n=333), only highly purified menotropin (HP-hMG); and group 3 (n=349), rFSH plus HP-hMG. One thousand seventy-nine oocyte recipients.


METHODS
Controlled ovarian stimulation.


METHODS
Controlled ovarian stimulation parameters, IVF outcome, and cost analysis.


RESULTS
No differences were found among the groups with respect to days of stimulation, gonadotropin dose, final E2 and P levels, number of oocytes retrieved, and cancellation rate. Similarly, there were no differences among the groups in terms of embryo development parameters. Moreover, implantation, pregnancy, and miscarriage rates with the three regimens were similar. However, the cost of rFSH was greater than that of the other protocols.


CONCLUSIONS
This study suggests that in the GnRH agonist protocol the three different gonadotropin regimens evaluated herein are equally effective. Protocols using HP-hMG would appear to be the best in terms of cost-effectiveness in an oocyte donation program.
Melo
Marco
M
Instituto Valenciano de Infertilidad, Universidad de Valencia, Department of Obsterics and Gynaecology, University Hospital Dr. Peset, Valencia, Spain. marcoabm@hotmail.com
Bellver
José
J
Garrido
Nicolás
N
Meseguer
Marcos
M
Pellicer
Antonio
A
Remohí
José
J
D000293:Adolescent; D000328:Adult; D017046:Cost Savings / Q000379:methods; D005260:Female; D005300:Fertility Agents, Female / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D005307:Fertilization in Vitro / Q000191:economics* / Q000379:methods*; D006062:Gonadotropins / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000191:economics / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018587:Oocyte Donation / Q000379:methods*; D010053:Ovary / Q000187:drug effects* / Q000502:physiology; D010062:Ovulation Induction / Q000191:economics / Q000379:methods; D011247:Pregnancy; D018873:Pregnancy Rate; D016896:Treatment Outcome; D055815:Young Adult
D005300:Fertility Agents, Female; D006062:Gonadotropins